ARQT
Arcutis Biotherapeutics, Inc. · Healthcare · Biotechnology
动量输入(同类管理人):
持有人广度 -12.5% ·
股份流向 +2.4% ·
净新建仓位 -14.3%
· 公式
集中增持:持股数量上升,持有人数量减少
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 14.37K | $352,080 | n/a | −1 |
| Q2 2026 | 104 | +8 | 69.45M | $1.82B | +11 | −3 |
| Q1 2026 | 99 | +1 | 69.94M | $1.65B | +6 | −6 |
| Q4 2025 | 97 | +2 | 70.50M | $2.05B | +3 | n/a |
| Q3 2025 | 16 | 0 | 32.55M | $613.65M | +1 | −2 |
| Q2 2025 | 14 | -2 | 28.30M | $396.73M | n/a | −2 |
| Q1 2025 | 13 | 0 | 11.91M | $186.25M | +1 | −1 |
| Q4 2024 | 13 | +1 | 15.11M | $210.56M | +1 | n/a |
| Q3 2024 | 11 | +1 | 9.54M | $88.77M | +2 | −1 |
| Q2 2024 | 10 | n/a | 8.25M | $76.75M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 8.53M | n/a | $119.63M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 2 | The Vanguard Group ✦ (被动) | 7.05M | n/a | $98.83M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (被动) | 4.53M | +1.2% | $63.47M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 2.58M | +1.4% | $36.21M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | D. E. Shaw & Co. ✦ | 2.16M | +8.7% | $30.33M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 1.49M | +78.9% | $20.83M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | Millennium Management ✦ | 910.84K | +92.3% | $12.77M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 375.23K | +51.2% | $5.26M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 9 | Norges Bank ✦ (被动) | 174.82K | -74.3% | $2.45M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 150.73K | n/a | $2.11M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 145.49K | -53.1% | $2.04M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 84.05K | +7.8% | $1.18M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 71.68K | -52.7% | $1.00M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | Wellington Management ✦ | 44.27K | -5.1% | $620,622 | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Marshall Wace | $905,681 | 曾为 0.0% |
| Renaissance Technologies | $340,936 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 267 持有人, 132.09M 股份, $3.07B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Director · 4.73K 股 · $127,325
Officer · 3.67K 股 · $91,853
Director · 4.73K 股 · $114,371
Officer · 9.99K 股 · $249,986
Director · 11.15K 股 · $279,028
Director · 27.05K 股 · $677,095
Director · 1.07K 股 · $27,912
Officer · 1.70K 股 · $45,819
Director · 4.73K 股 · $123,835
Officer · 6.70K 股 · $174,767
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论